Senthamil R. Selvan

1.6k total citations
41 papers, 1.1k citations indexed

About

Senthamil R. Selvan is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Senthamil R. Selvan has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 16 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Senthamil R. Selvan's work include Immunotherapy and Immune Responses (18 papers), Cancer Immunotherapy and Biomarkers (10 papers) and CAR-T cell therapy research (9 papers). Senthamil R. Selvan is often cited by papers focused on Immunotherapy and Immune Responses (18 papers), Cancer Immunotherapy and Biomarkers (10 papers) and CAR-T cell therapy research (9 papers). Senthamil R. Selvan collaborates with scholars based in United States, India and Morocco. Senthamil R. Selvan's co-authors include Takami Sato, Michael J. Mastrangelo, Mizue Terai, Yutaka Tamura, Vitali Alexeev, Robert O. Dillman, Mepur H. Ravindranath, Dan A. Erkes, Carol DePriest and John P. Dowling and has published in prestigious journals such as Cancer Research, Biochemical and Biophysical Research Communications and International Journal of Cancer.

In The Last Decade

Senthamil R. Selvan

41 papers receiving 1.1k citations

Peers

Senthamil R. Selvan

IMMUN

ONCOL

MB

CR

PRM

Yinyan Xu United States

Zhengguo Zhang China

Atieh Pourbagheri‐Sigaroodi Iran

Hongyan Liu China

Yuxiang Wang China

Doris Vokurková Czechia

Raoul Salup United States

Mengyao Wu China

Yinyan Xu United States

Senthamil R. Selvan

723 ×1.3

IMMUN

568 ×1.1

ONCOL

396 ×1.3

MB

68 ×0.7

CR

60 ×0.6

PRM

Citations per year, relative to Senthamil R. Selvan Senthamil R. Selvan (= 1×) peers Yinyan Xu

Countries citing papers authored by Senthamil R. Selvan

Since Specialization

Citations

This map shows the geographic impact of Senthamil R. Selvan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Senthamil R. Selvan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Senthamil R. Selvan more than expected).

Fields of papers citing papers by Senthamil R. Selvan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Senthamil R. Selvan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Senthamil R. Selvan. The network helps show where Senthamil R. Selvan may publish in the future.

Co-authorship network of co-authors of Senthamil R. Selvan

This figure shows the co-authorship network connecting the top 25 collaborators of Senthamil R. Selvan. A scholar is included among the top collaborators of Senthamil R. Selvan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Senthamil R. Selvan. Senthamil R. Selvan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Ravindranath, Mepur H., et al.. (2022). Four Faces of Cell-Surface HLA Class-I: Their Antigenic and Immunogenic Divergence Generating Novel Targets for Vaccines. Vaccines. 10(2). 339–339. 4 indexed citations

2.

Venkateswaran, Kodumudi S., Jawad Sarwar, Senthamil R. Selvan, et al.. (2022). Validation of a Lateral Flow Test for the Presumptive Identification of the Presence of Burkholderia mallei or Burkholderia pseudomallei in Environmental Samples. Health Security. 20(2). 154–163. 1 indexed citations

3.

Venkateswaran, Kodumudi S., Jawad Sarwar, Senthamil R. Selvan, et al.. (2022). Rapid Presumptive Identification of Burkholderia mallei and Burkholderia pseudomallei Clinical Isolates Using a Highly Specific Lateral Flow Assay. Health Security. 20(2). 164–171. 1 indexed citations

4.

Selvan, Senthamil R., et al.. (2021). Functional Profiling of Head and Neck/Esophageal Squamous Cell Carcinoma to Predict Cetuximab Response. Cancer Biotherapy and Radiopharmaceuticals. 3 indexed citations

5.

Selvan, Senthamil R., et al.. (2020). Application of Varma Kalai (art of vital points) in autism spectrum disorder. European Journal of Integrative Medicine. 41. 101231–101231. 1 indexed citations

6.

Dobbin, Kevin K., Alessandra Cesano, John Alvarez, et al.. (2016). Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations. Journal for ImmunoTherapy of Cancer. 4(1). 77–77. 78 indexed citations

7.

Selvan, Senthamil R., John P. Dowling, William Kevin Kelly, & Jianqing Lin. (2016). Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies. Current Cancer Drug Targets. 16(9). 755–764. 61 indexed citations

8.

Nagarathna, Raghuram, et al.. (2015). Remedial Yoga module improves symptoms of irritable bowel syndrome: Replication in the Wait-list group and sustained improvements at 6 months. European Journal of Integrative Medicine. 7(6). 609–616. 6 indexed citations

9.

Nagarathna, Raghuram, et al.. (2015). Remedial yoga module remarkably improves symptoms in irritable bowel syndrome patients: A 12-week randomized controlled trial. European Journal of Integrative Medicine. 7(6). 595–608. 25 indexed citations

10.

Dillman, Robert O., Gary B. Fogel, Andrew N. Cornforth, et al.. (2011). Features Associated with Survival in Metastatic Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines. Cancer Biotherapy and Radiopharmaceuticals. 26(4). 407–415. 16 indexed citations

11.

Dillman, Robert O., Richard B. Kim, Christopher Duma, et al.. (2010). Durable Complete Response of Refractory, Progressing Metastatic Melanoma After Treatment with a Patient-Specific Vaccine. Cancer Biotherapy and Radiopharmaceuticals. 25(5). 553–557. 18 indexed citations

12.

Dillman, Robert O., Senthamil R. Selvan, Patric M. Schiltz, et al.. (2009). Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Antitumor Vaccines in Patients with Metastatic Melanoma: Final Report. Cancer Biotherapy and Radiopharmaceuticals. 24(3). 311–319. 56 indexed citations

13.

Selvan, Senthamil R., et al.. (2007). Monitoring response to treatment in melanoma patients: Potential of a serum glycomic marker. International Journal of Cancer. 122(6). 1374–1383. 12 indexed citations

14.

Dillman, Robert O., Senthamil R. Selvan, Patric M. Schiltz, et al.. (2006). Dendritic cells loaded with proliferating autologous tumor cells as patient-specific vaccines in recurrent or metastatic melanoma and renal cell cancer. Cancer Research. 66. 678–678. 1 indexed citations

15.

Dillman, Robert O., Linda D. Beutel, Shankar K. Nayak, et al.. (2005). Cancer Vaccine Potency: Is There a Dose/Response Relationship for Patient-Specific Vaccines and Clinical Outcomes?. Cancer Biotherapy and Radiopharmaceuticals. 20(4). 373–378. 10 indexed citations

16.

Selvan, Senthamil R., et al.. (2004). Characterization of autologous melanoma cell lines for vaccine therapy: Pattern of expression of tumor-associated antigens. Cancer Research. 64. 286–286. 1 indexed citations

17.

Dillman, Robert O., Senthamil R. Selvan, Patric M. Schiltz, et al.. (2004). Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim Analysis. Cancer Biotherapy and Radiopharmaceuticals. 19(5). 658–665. 34 indexed citations

18.

Dillman, Robert O., Senthamil R. Selvan, Patric M. Schiltz, et al.. (2004). Phase I/II Trial of Melanoma Patient–Specific Vaccine of Proliferating Autologous Tumor Cells, Dendritic Cells, and GM-CSF: Planned Interim Analysis. Cancer Biotherapy and Radiopharmaceuticals. 19(5). 658–665. 16 indexed citations

19.

Dillman, Robert O., Neil M. Barth, Senthamil R. Selvan, et al.. (2004). Phase I/II Trial of Autologous Tumor Cell Line–Derived Vaccines for Recurrent or Metastatic Sarcomas. Cancer Biotherapy and Radiopharmaceuticals. 19(5). 581–588. 31 indexed citations

20.

Dillman, Robert O., Neil M. Barth, Senthamil R. Selvan, et al.. (2004). Phase I/II Trial of Autologous Tumor Cell Line–Derived Vaccines for Recurrent or Metastatic Sarcomas. Cancer Biotherapy and Radiopharmaceuticals. 19(5). 581–588. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact